Global Pneumococcal Vaccine Market 2016-2020




$ 2500

In Stock

About Pneumococcus

Pneumococcus (Streptococcus pneumoniae), a pathogenic bacterium, is the leading cause of serious illness worldwide. It is the major cause of pneumonia, blood infections, meningitis, sinusitis, and middle ear infections (otitis media). Pneumococcal infections affect children younger than five years and older people (65 years and older), and it is among the leading infectious disease. It kills almost 1.6 million people (including over 800,000 children under five years) every year. It can be prevented by vaccination and involves the introduction of a dead or weakened antigen into the human body. This produces lymphocytes to counter the infection and any future invasions by that antigen.

Technavios analysts forecast the global pneumococcal vaccine market to grow at a CAGR of 13.69% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global pneumococcal vaccine market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent pneumococcal infections.

The market is divided into the following segments based on geography:

Technavio's report, Global Pneumococcal Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline (GSK)

Other prominent vendors
Beijing Minhai Biotechnology
Eli Lilly
Genocea Biosciences
Nuron Biotech
Panacea Biotec (India)
S K Chemicals
Serum Institute of India
Valneva Austria

Market driver
Inclusion in NIP
For a full, detailed list, view our report

Market challenge
Inadequate vaccine coverage
For a full, detailed list, view our report

Market trend
Expansion of marketing territories
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

PART 01: Executive summary
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Pneumococcal vaccine: Overview
Vaccine approval process
PART 06: Market landscape
Market overview
Five forces analysis
Market segmentation by composition
Global PCV market
Market overview
Global PPV market
Market overview
PART 07: Geographical segmentation
Pneumococcal vaccine market in Americas
Pneumococcal vaccine market in EMEA
Pneumococcal vaccines market in APAC
PART 08: Market drivers
Inclusion in NIP
Broad serotype coverage
Global action plans for pneumonia vaccines
PART 09: Impact of drivers
PART 10: Market challenges
Inadequate vaccine coverage
Require cold storage
High risk and cost involved in vaccine development
Stringent regulatory guidelines
PART 11: Impact of drivers and challenges
PART 12: Market trends
Expansion of marketing territories
Emergence of protein-based combination pneumococcal vaccines
AMC for pneumococcal vaccines
Publicprivate initiatives
PART 13: Vendor landscape
Competitive scenario
Key news
Other prominent vendors
PART 14: Appendix
List of abbreviations
PART 15: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Market share of pneumococcus vaccine market in global pharmaceutical market 2015
Exhibit 03: Market share of pneumococcal vaccine markets in global pharmaceutical market, 2015
Exhibit 04: Global pneumococcal vaccine market snapshot
Exhibit 05: Milestones in pneumococcus vaccines development
Exhibit 06: Key buying criteria for pneumococcal vaccine 2015
Exhibit 07: Impact of key customer segments on market 2015
Exhibit 08: Requirements for a BLA submission
Exhibit 09: Types of development necessary to reach vaccine licensing stage
Exhibit 10: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
Exhibit 11: Regulatory testing of licensed vaccines
Exhibit 12: Economic burden of pneumococcal disease in children 2015
Exhibit 13: Total global costs for treating pneumococcal disease 2015 ($ billions)
Exhibit 14: Global pneumococcal vaccine market snapshot: Developed and emerging markets 2015
Exhibit 15: Overview of vaccine-related acquisitions 2005-2012
Exhibit 16: Global pneumococcal vaccine market 2015-2020 ($ billions)
Exhibit 17: Approved pneumococcal serotypes
Exhibit 18: Global pneumococcal vaccines market by volume 2013-2020 (million doses)
Exhibit 19: Impact of drivers and challenges on global pneumococcal vaccine market
Exhibit 20: Five forces analysis
Exhibit 21: Global pneumococcal vaccines market: Segmentation by composition 2015-2020
Exhibit 22: Global pneumococcal vaccines market segmentation by application 2015
Exhibit 23: Global pneumococcal vaccines market segmentation: Growth cycle analysis
Exhibit 24: Global supply and demand of PCV ($ millions) (2010-2017)
Exhibit 25: Price evolution of PCV (2009-2015)
Exhibit 26: Global PCV market 2015-2020 ($ billions)
Exhibit 27: Opportunity analysis of global conjugate vaccines market by composition
Exhibit 28: Global PPV market 2015-2020 ($ billions)
Exhibit 29: Opportunity analysis of global polysaccharide vaccines market by composition
Exhibit 30: Global PPV market segmentation by composition 2015
Exhibit 31: Global pneumococcal vaccine market by geography 2015
Exhibit 32: Global pneumococcal vaccine market: Geographical outlook (2015-2020)
Exhibit 33: Global pneumococcal vaccine market: Geographical outlook 2015
Exhibit 34: Segmentation of global pneumococcal vaccine market by region: Market growth lifecycle analysis 2015
Exhibit 35: Opportunity analysis of pneumococcal vaccine market in Americas
Exhibit 36: Pneumococcal vaccine market in Americas 2015-2020 ($ billions)
Exhibit 37: Pneumococcal vaccine market in Americas: PEST analysis
Exhibit 38: Opportunity analysis of pneumococcal vaccine market in EMEA
Exhibit 39: Pneumococcal vaccine market in EMEA 2015-2020 ($ billions)
Exhibit 40: Pneumococcal vaccine market in EMEA: PEST analysis
Exhibit 41: Opportunity analysis of pneumococcal vaccine market in APAC
Exhibit 42: Pneumococcal vaccine market in APAC 2015-2020 ($ billions)
Exhibit 43: Pneumococcal vaccine market in APAC: PEST analysis
Exhibit 44: Impact of drivers
Exhibit 45: A typical cold chain process
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Global pneumococcal vaccines market: Impact assessment of key trends 2015
Exhibit 48: Developing countries and their approval status for GAVI support
Exhibit 49: Pneumococcal procurement volumes through AMC (million doses)
Exhibit 50: Geographical presence of top vendors in global pneumococcal vaccine market 2015
Exhibit 51: Competitive assessment of vendors
Exhibit 52: Key vendors: Geographical presence 2015
Exhibit 53: Pfizer: YoY revenue and growth rate of Prevnar 2013-2015 ($ billions)
Exhibit 54: Pfizer: Revenue forecast of Prevnar 2016-2020 ($ billions)
Exhibit 55: Pfizer: Metrics analysis
Exhibit 56: Sanofi: YoY revenue growth of Meningitis/pneumonia vaccines 2013-2015 ($ millions)
Exhibit 57: Geographical segmentation of meningitis vaccines/PCVs by revenue 2015
Exhibit 58: Sanofi: Metrics analysis
Exhibit 59: GSK: YoY revenue and growth rate of Synflorix 2013-2015 ($ millions)
Exhibit 60: GSK: YoY geographical revenue of Synflorix 2013-2015 ($ millions)
Exhibit 61: GSK: Geographical segmentation of Synflorix 2015
Exhibit 62: Synflorix price per dose in different countries
Exhibit 63: GSK: Metrics analysis
Exhibit 64: Merck: YoY revenue growth of Pneumovax 23 2013-2015 ($ millions)
Exhibit 65: Merck: Metrics analysis